Shin Nippon Biomedical Laboratories, Ltd. Share Price BOERSE MUENCHEN

Equities

YB3

JP3379950003

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 02:43:19 29/05/2024 pm IST 5-day change 1st Jan Change
8 EUR 0.00% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. -2.44% -25.93%

Financials

Sales 2024 26.45B 168M 155M 14.03B Sales 2025 * 30.5B 194M 179M 16.17B Capitalization 58.49B 372M 343M 31.02B
Net income 2024 5.53B 35.2M 32.46M 2.93B Net income 2025 * 4.3B 27.37M 25.23M 2.28B EV / Sales 2024 2.39 x
Net Debt 2024 * 19.51B 124M 114M 10.35B Net Debt 2025 * 22.77B 145M 134M 12.08B EV / Sales 2025 * 2.66 x
P/E ratio 2024
11.4 x
P/E ratio 2025 *
13.6 x
Employees -
Yield 2024
3.29%
Yield 2025 *
3.56%
Free-Float 48.8%
More Fundamentals * Assessed data
Dynamic Chart
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval MT
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers. CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals MT
Sector Update: Health Care Stocks Higher Premarket Monday MT
Bank Earnings in Focus as US Equity Futures Tread Water MT
Top Premarket Gainers MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million. CI
More news
1 week-2.44%
Current month-10.61%
1 month-10.11%
3 months-20.79%
6 months-20.79%
Current year-25.93%
More quotes
1 week
7.85
Extreme 7.85
8.00
1 month
7.85
Extreme 7.85
9.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 01/81/01
Director of Finance/CFO 55 01/02/01
Compliance Officer - 01/84/01
Members of the board TitleAgeSince
Chief Executive Officer 65 01/81/01
Director/Board Member 38 01/17/01
Sales & Marketing 64 01/02/01
More insiders
Date Price Change
29/24/29 8 0.00%
28/24/28 8 +1.91%
27/24/27 7.85 0.00%
24/24/24 7.85 -0.63%
23/24/23 7.9 0.00%

Real-time BOERSE MUENCHEN, May 29, 2024 at 02:43 pm IST

More quotes
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1,405 JPY
Average target price
2,800 JPY
Spread / Average Target
+99.29%
Consensus